Developmental Research The Developmental Research Program for the Lymphoma SPORE is designed to identify and selectively fund innovative and pilot studies of lymphoma translational research within and outside of the University of Rochester and the University of Arizona. Once annually, proposals will be requested. A senior faculty committee, which includes representation of lay advocates, under the direction of Hartmut Land, Ph.D., will review the detailed applications, gives them a priority score, and recommends projects for funding to the Lymphoma SPORE committee, who will make the final decision. The proposals will be evaluated for originality, scientific design, and particular attention to translational relevance. In addition, standard NIH review criteria for significance, approach, innovation, investigator, and environment will be applied. There will be no discrimination based on age, sex, race, religion, national origin, etc, and proposals from women and underrepresented minorities will be encouraged. Proposals with the highest scientific merit and directly related to lymphoma translational research will be considered for one or two years of funding. These projects may utilize the core facilities within the SPORE. The primary objectives of this developmental research program are as follows: 1. Encourage laboratory and clinical investigators to apply their expertise toward lymphoma translational research. 2. Foster collaboration between SPORE participants, and other lymphoma investigators. 3. Provide seed money for research projects that will ultimately compete for peer-reviewed funding, or become main projects within the SPORE proposal.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA130805-05
Application #
8381192
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
5
Fiscal Year
2012
Total Cost
$59,128
Indirect Cost
$47,346
Name
University of Rochester
Department
Type
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Runckel, Kyle; Barth, Matthew J; Mavis, Cory et al. (2018) The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma. Blood Adv 2:3516-3525
Akhenblit, Paul J; Hanke, Neale T; Gill, Alexander et al. (2016) Assessing Metabolic Changes in Response to mTOR Inhibition in a Mantle Cell Lymphoma Xenograft Model Using AcidoCEST MRI. Mol Imaging 15:
Havas, Aaron P; Rodrigues, Kameron B; Bhakta, Anvi et al. (2016) Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma. Cancer Biol Ther 17:1240-1252
Holkova, Beata; Kmieciak, Maciej; Bose, Prithviraj et al. (2016) Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. Leuk Lymphoma 57:635-43
Nedelkovska, Hristina; Rosenberg, Alexander F; Hilchey, Shannon P et al. (2016) Follicular Lymphoma Tregs Have a Distinct Transcription Profile Impacting Their Migration and Retention in the Malignant Lymph Node. PLoS One 11:e0155347
Holkova, Beata; Zingone, Adriana; Kmieciak, Maciej et al. (2016) A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res 22:1067-75
Zhou, L; Zhang, Y; Chen, S et al. (2015) A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Leukemia 29:807-18
Jaramillo, Melba C; Briehl, Margaret M; Batinic-Haberle, Ines et al. (2015) Manganese (III) meso-tetrakis N-ethylpyridinium-2-yl porphyrin acts as a pro-oxidant to inhibit electron transport chain proteins, modulate bioenergetics, and enhance the response to chemotherapy in lymphoma cells. Free Radic Biol Med 83:89-100
Chen, Liu Qi; Howison, Christine M; Spier, Catherine et al. (2015) Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models. Leuk Lymphoma 56:1432-9
Kiebala, Michelle; Skalska, Jolanta; Casulo, Carla et al. (2015) Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach. Exp Hematol 43:89-99

Showing the most recent 10 out of 115 publications